Hematology/Oncology News

CHICAGO — In this Healio video exclusive, Jessi Gold, MD, MS, discusses her keynote address during the Women in Medicine Summit on self-disclosure reciprocity and how sharing our stories changes culture.

Researchers confirmed that head and neck melanomas have distinct biological characteristics that make it more adverse to patients yet more responsive to immunotherapy, according to a study.

Use of post-transplant cyclophosphamide prophylaxis to prevent graft-versus-host disease could greatly expand access to hematopoietic stem cell transplantation, according to results of a retrospective study.

A mouthwash-based biomarker test has demonstrated efficacy for detecting risk of head and neck cancer recurrence, according to results of a nonrandomized clinical trial.

False-positive mammography results discouraged women to return for further screenings, results from an observational cohort study published in the Annals of Internal Medicine showed.

Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.

Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.

Pembrolizumab significantly extended OS at 10 years compared with ipilimumab for patients with advanced melanoma, according to study results presented at ESMO Congress.

The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.

The addition of six cycles of radium-223 to first-line enzalutamide extended radiographic PFS for men with metastatic castration-resistant prostate cancer, according to results of a randomized phase 3 trial.